2010: Established joint venture in Tianjin (China) and secured state funding support; commissioned transdermal production line in China.

2009: Secured pharmaceutical dossier and manufacturing process for complementary CDx treatment to NicoTestâ„¢; global exclusivity deal with GE Healthcare for supply of key Dx components; acquired three patent families and a transdermal production technology from Fertin Pharma.

2008: Successful clinical validation of NicoTestâ„¢ in UK NHS; first NicoTestâ„¢ distribution agreement for US/Canada.

2006: £1m of funding was committed from Oxford Gateway Fund 2, the Great Eastern Investment Fund (GEIFV) and private individuals

2005: Successful test-marketing of lead product NicoTestâ„¢

2004: Seed funding from management, founders and the Oxford Gateway Fund No.2

2003: Company founded by Mark Tucker and Robert Walton as spin-out from University of Oxford and Cancer Research UK